Texas Permanent School Fund Corp Has $18.87 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Texas Permanent School Fund Corp boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 257,652 shares of the biopharmaceutical company’s stock after purchasing an additional 290 shares during the period. Texas Permanent School Fund Corp’s holdings in Gilead Sciences were worth $18,873,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GILD. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter worth about $896,000. Integrated Wealth Concepts LLC lifted its position in shares of Gilead Sciences by 1.2% in the third quarter. Integrated Wealth Concepts LLC now owns 28,215 shares of the biopharmaceutical company’s stock worth $2,114,000 after buying an additional 338 shares during the last quarter. Creative Planning lifted its position in shares of Gilead Sciences by 0.5% in the third quarter. Creative Planning now owns 152,961 shares of the biopharmaceutical company’s stock worth $11,463,000 after buying an additional 767 shares during the last quarter. Integrated Advisors Network LLC lifted its position in shares of Gilead Sciences by 1.7% in the third quarter. Integrated Advisors Network LLC now owns 14,543 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 238 shares during the last quarter. Finally, Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday. Oppenheimer reiterated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus price target of $84.00.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock traded up $1.22 during trading hours on Thursday, hitting $69.97. The company had a trading volume of 9,595,036 shares, compared to its average volume of 7,507,853. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The firm has a market capitalization of $87.17 billion, a price-to-earnings ratio of 192.25, a PEG ratio of 2.87 and a beta of 0.18. The firm’s fifty day moving average is $66.23 and its 200 day moving average is $71.88. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.37 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.40%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.